

ISEC HEALTHCARE LTD.

(Company Registration No.201400185H)

**Unaudited Financial Statement and Dividend Announcement
 For the Financial Year Ended 31 December 2020**
PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF-YEAR AND FULL YEAR RESULTS

1(a)(i) An income statement and statement of comprehensive income, or a statement of comprehensive income for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year.

	Group 3 Months Ended			Group 12 Months Ended		
	31 December 2020 (Unaudited) S\$'000	31 December 2019 (Unaudited) S\$'000	Change %	31 December 2020 (Unaudited) S\$'000	31 December 2019 (Audited) S\$'000	Change %
Revenue	10,119	11,617	-13%	36,327	42,872	-15%
Cost of sales	(5,379)	(6,163)	-13%	(20,270)	(22,823)	-11%
Gross profit	4,740	5,454	-13%	16,057	20,049	-20%
Other item of income						
Other income	369	263	40%	1,325	702	89%
Other items of expense						
Selling and distribution expenses	(7)	(24)	-71%	(41)	(60)	-32%
Administrative expenses	(2,125)	(2,411)	-12%	(8,345)	(8,677)	-4%
Other expenses	(691)	(189)	NM	(2,048)	(1,818)	-13%
Finance costs	(132)	(66)	100%	(424)	(257)	65%
Share of results of associate	5	(2)	NM	(18)	(34)	-47%
Profit before income tax	2,159	3,025	-29%	6,506	9,905	-34%
Income tax expense	(738)	(765)	-4%	(2,055)	(2,656)	-23%
Profit for the financial period	1,421	2,260	-37%	4,451	7,249	-39%

NM – Not meaningful

ISEC HEALTHCARE LTD.

(Company Registration No.201400185H)

	Group			Group		
	3 Months Ended			12 Months Ended		
	31	31	Change	31	31	Change
	December	December		December	December	
2020	2019		2020	2019		
(Unaudited)	(Unaudited)		(Unaudited)	(Audited)		
	S\$'000	S\$'000	%	S\$'000	S\$'000	%
Other comprehensive income						
<i>Items that may be reclassified subsequently to profit or loss:</i>						
Foreign currency translation of subsidiaries	(38)	(42)	-10%	72	(38)	NM
Other comprehensive income for the financial period, net of tax	(38)	(42)	-10%	72	(38)	NM
Total comprehensive income for the financial period	1,383	2,218	-38%	4,523	7,211	-37%
Profit attributable to:						
Owners of the parent	1,472	2,344	-37%	4,690	7,465	-37%
Non-controlling interests	(51)	(84)	-39%	(239)	(216)	11%
Profit for the financial period	1,421	2,260	-37%	4,451	7,249	-39%
Total comprehensive income attributable to:						
Owners of the parent	1,434	2,303	-38%	4,762	7,431	-36%
Non-controlling interests	(51)	(85)	-40%	(239)	(220)	9%
Total comprehensive income for the financial period	1,383	2,218	-38%	4,523	7,211	-37%

NM – Not meaningful

1(a)(ii) Notes to Consolidated Statement of Comprehensive Income

Profit before income tax is arrived after charging/(crediting) the following:

	Group			Group		
	3 Months Ended		Change	12 Months Ended		Change
	31 December	31 December		31 December	31 December	
	2020	2019	2020	2019		
(Unaudited)	(Unaudited)	(Unaudited)	(Audited)			
	S\$'000	S\$'000	%	S\$'000	S\$'000	%
Depreciation of property, plant and equipment - cost of sales	180	169	7%	719	657	9%
Depreciation of right-of-use assets - cost of sales	115	112	3%	453	403	12%
Depreciation of property, plant and equipment – administrative expenses	95	95	0%	398	387	3%
Depreciation of right-of-use assets – administrative expenses	282	252	12%	1,085	1,073	1%
Amortisation of intangible assets – other expenses	141	140	1%	561	560	0%
Amortisation of intangible assets – administrative expenses	9	15	-40%	36	62	-42%
Interest income	(63)	(122)	-48%	(298)	(491)	-39%
Interest income – net investment in sublease	(2)	(2)	0%	(8)	(9)	-11%
Other income – government grants	(136)	(65)	NM	(639)	(85)	NM
Other income – rental rebate	(10)	-	NM	(132)	-	NM
Interest expense – loans	29	-	NM	43	-	NM
Interest expense – lease liabilities	75	65	15%	287	254	13%
(Gain)/loss on exchange differences, net	(25)	16	NM	(34)	14	NM
(Gain)/loss on disposal of plant and equipment	(1)	(2)	-50%	(16)	1	NM
Plant and equipment written-off	-	-	NM	-	18	-100%
Allowance for/(write-back of) expected credit losses, net	6	4	50%	(12)	7	NM
Bad debts written-off	-	1	-100%	-	1	-100%
Impairment loss for goodwill	550	-	NM	1,484	1,180	26%
Share-based compensation expenses	25	-	NM	71	-	NM
Profit guarantee from vendors ⁽¹⁾ of subsidiaries acquired	(135)	(63)	NM	(135)	(63)	NM

NM – Not meaningful

(1) Vendors refer to the previous shareholders of JL Medical (Bukit Batok) Pte. Ltd., JL Medical (Sembawang) Pte. Ltd., JL Medical (Woodlands) Pte. Ltd. and JL Medical (Yew Tee) Pte. Ltd. (collectively, “JLM Companies”) prior to 1 December 2016.

1(b)(i) A statement of financial position for the issuer and group, together with a comparative statement as at the end of the immediately preceding financial year

	Group		Company	
	31 December 2020 (Unaudited) S\$'000	31 December 2019 (Audited) S\$'000	31 December 2020 (Unaudited) S\$'000	31 December 2019 (Audited) S\$'000
ASSETS				
Non-current assets				
Property, plant and equipment	10,141	3,957	13	25
Right-of-use assets	4,754	4,130	126	45
Intangible assets - goodwill	42,252	33,712	-	-
Intangible assets - others	2,171	2,646	-	-
Investment in subsidiaries	-	-	56,855	52,669
Investment in associate	168	186	-	-
Net investment in sublease	109	181	-	-
Deferred tax assets	51	114	7	12
	59,646	44,926	57,001	52,751
Current assets				
Inventories	1,333	1,208	-	-
Trade receivables, net ⁽¹⁾	2,337	2,563	-	6
Other receivables and deposits	737	522	12,504	9,966
Prepayments	247	237	12	20
Net investment in sublease	56	60	-	-
Cash and cash equivalents ⁽¹⁾	24,124	25,657	6,109	5,764
	28,834	30,247	18,625	15,756
TOTAL ASSETS	88,480	75,173	75,626	68,507
EQUITY AND LIABILITIES				
EQUITY				
Share capital	70,054	64,741	70,054	64,741
Treasury share reserve	(105)	(105)	(105)	(105)
Other reserves	(7,397)	(7,540)	71	-
Retained earnings	8,557	6,529	5,033	3,359
Equity attributable to owners of Company	71,109	63,625	75,053	67,995
Non-controlling interests	580	478	-	-
TOTAL EQUITY	71,689	64,103	75,053	67,995
LIABILITIES				
Non-current liabilities				
Other payables	558	-	-	-
Loans	3,141	-	-	-
Provisions	163	162	21	20
Lease liabilities	3,610	3,170	55	-
Deferred tax liabilities	378	451	-	-
	7,850	3,783	76	20

ISEC HEALTHCARE LTD.

(Company Registration No.201400185H)

	Group		Company	
	31 December 2020 (Unaudited) S\$'000	31 December 2019 (Audited) S\$'000	31 December 2020 (Unaudited) S\$'000	31 December 2019 (Audited) S\$'000
Current liabilities				
Trade payables	1,098	1,384	-	-
Other payables	2,338	602	210	71
Advances and contract liabilities	212	227	-	-
Accrued expenses	512	472	148	193
Payroll payable	1,423	2,060	41	165
Loans	866	-	-	-
Lease liabilities	1,646	1,544	73	47
Current income tax payable	846	998	25	16
	8,941	7,287	497	492
TOTAL LIABILITIES	16,791	11,070	573	512
TOTAL EQUITY AND LIABILITIES	88,480	75,173	75,626	68,507

(1) Breakdown of the following in the respective currencies:

	Group		Company	
	31 December 2020 S\$'000	31 December 2019 S\$'000	31 December 2020 S\$'000	31 December 2019 S\$'000
Trade receivables, net denominated in the following currencies:				
Singapore Dollar	1,145	1,449	-	6
Ringgit Malaysia	1,190	1,114	-	-
Myanmar Kyat	2	*	-	-
	2,337	2,563	-	6
Cash and cash equivalents denominated in the following currencies:				
Singapore Dollar	9,405	8,822	6,109	5,764
Ringgit Malaysia	14,491	16,795	-	-
Myanmar Kyat	31	13	-	-
United States Dollar	197	27	-	-
	24,124	25,657	6,109	5,764

* Less than S\$1,000.

1(b)(ii) Aggregate amount of group's borrowings and debt securities
Amount repayable in one year or less, or on demand

As at 31 December 2020		As at 31 December 2019	
Secured S\$'000	Unsecured S\$'000	Secured S\$'000	Unsecured S\$'000
866	1,646 ⁽¹⁾	-	1,544 ⁽¹⁾

Amount repayable after one year

As at 31 December 2020		As at 31 December 2019	
Secured S\$'000	Unsecured S\$'000	Secured S\$'000	Unsecured S\$'000
3,141	3,610 ⁽¹⁾	-	3,170 ⁽¹⁾

(1) Unsecured borrowings relate to leases recognised under SFRS(I) 16 Leases.

Details of any collateral

As at 31 December 2020, the Group's secured loan of S\$4.007 million (FY2019: nil) is secured by the land and building for which the loan was entered.

1(c) A statement of cash flows for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year.

Consolidated Statement of Cash Flows

	Group 3 Months Ended		Group 12 Months Ended	
	31 December 2020 (Unaudited) S\$'000	31 December 2019 (Unaudited) S\$'000	31 December 2020 (Unaudited) S\$'000	31 December 2019 (Audited) S\$'000
Cash flows from operating activities				
Profit before income tax	2,159	3,025	6,506	9,905
Adjustments for:				
Allowance for/(write-back of) expected credit losses, net	6	4	(12)	7
Amortisation of intangible assets	150	155	597	622
Bad debts written-off	-	1	-	1
Depreciation of property, plant and equipment and right-of-use assets	672	628	2,655	2,520
Interest income	(65)	(124)	(306)	(500)
Interest expense	132	66	424	257
Impairment loss for goodwill	550	-	1,484	1,180
Other income from rental rebate	(10)	-	(132)	-
(Gain)/loss on disposal of plant and equipment	(1)	(2)	(16)	1
Plant and equipment written-off	-	-	-	18
Share-based compensation expenses	25	-	71	-
Share of results of associate	(5)	2	18	34
Operating cash flows before working capital changes	3,613	3,755	11,289	14,045
Working capital changes:				
- Inventories	3	(88)	(11)	(93)
- Trade and other receivables	325	(514)	92	(89)
- Prepayments	24	6	(2)	(47)
- Trade and other payables	205	1,047	(1,218)	652
Cash generated from operations	4,170	4,206	10,150	14,468
Income tax paid	(806)	(533)	(2,276)	(2,805)
Net cash generated from operating activities	3,364	3,673	7,874	11,663
Cash flows from investing activities				
Proceeds from disposal of plant and equipment	1	-	1	16
Purchase of property, plant and equipment ⁽¹⁾	(150)	(249)	(2,314)	(1,361)
Purchase of intangible assets	(16)	(2)	(105)	(2)
Acquisition of a subsidiary, net of cash acquired	-	-	(2,946)	-
Interest received	63	117	298	471
Net cash used in investing activities	(102)	(134)	(5,066)	(876)

ISEC HEALTHCARE LTD.

(Company Registration No.201400185H)

	Group 3 Months Ended		Group 12 Months Ended	
	31 December 2020 (Unaudited) S\$'000	31 December 2019 (Unaudited) S\$'000	31 December 2020 (Unaudited) S\$'000	31 December 2019 (Audited) S\$'000
Cash flows from financing activities				
Dividends paid	-	-	(2,662)	(10,966)
Repayment of loans ⁽¹⁾	(213)	-	(284)	-
Subscription of shares in subsidiaries by non-controlling interests	-	-	341	651
Share issue expenses	-	-	(16)	(15)
Purchase of treasury shares	-	-	-	(105)
Purchase of shares in subsidiary from non-controlling interest	-	-	-	(80)
Principal element of lease liabilities	(348)	(324)	(1,412)	(1,460)
Interest paid – lease liabilities	(73)	(54)	(279)	(235)
Interest paid – loan ⁽¹⁾	(29)	-	(33)	-
Net cash used in financing activities	(663)	(378)	(4,345)	(12,210)
Net increase/(decrease) in cash and cash equivalents	2,599	3,161	(1,537)	(1,423)
Cash and cash equivalents at beginning of financial period	21,544	22,508	25,657	27,105
Effects of exchange rate changes on cash and cash equivalents	(19)	(12)	4	(25)
Cash and cash equivalents at end of financial period	24,124	25,657	24,124	25,657
(1) Non-cash transaction - investing and financing activities				
Purchase of property partially financed through bank loan	-	-	4,254	-

On 6 August 2020, ISEC (Penang) Sdn. Bhd., a wholly-owned indirect subsidiary of the Company, entered into a 5-year term bank loan to partially finance the acquisition of land and building, with an aggregate cost of RM18,922,000 (equivalent to S\$6,191,000), of which RM13,000,000 (equivalent to S\$4,254,000) was satisfied by the bank loan. The loan bears a floating interest rate of the bank's Cost of Funds + 0.5% margin per annum and is secured by the land and building for which the loan was entered. The interest rate for the period from August to December 2020 was 2.85%.

The remaining balance of RM5,922,000 (equivalent to S\$1,937,000) was satisfied by the Group's cash and included in purchase of property, plant and equipment.

ISEC HEALTHCARE LTD.

(Company Registration No.201400185H)

1(d)(i) A statement for the issuer and group showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year

Statements of Changes in Equity

Group (Unaudited)	Attributable to owners of the company									Total equity S\$'000
	Share capital	Treasury share reserve	Foreign currency translation reserve	Merger reserve	Capital reserve	Share option reserve	Retained earnings	Equity attributable to owners of the company	Non-controlling interests	
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	
At 1 January 2020	64,741	(105)	495	(3,572)	(4,463)	-	6,529	63,625	478	64,103
Profit for the financial period	-	-	-	-	-	-	3,218	3,218	(188)	3030
Other comprehensive income										
Foreign currency translation	-	-	110	-	-	-	-	110	-	110
Total comprehensive income for the financial period	-	-	110	-	-	-	3,218	3,328	(188)	3,140
Transactions with owners of the Company										
Issuance of ordinary shares ⁽¹⁾	5,329	-	-	-	-	-	-	5,329	-	5,329
Shares issue expenses	(16)	-	-	-	-	-	-	(16)	-	(16)
Dividends	-	-	-	-	-	-	(2,662)	(2,662)	-	(2,662)
Grant of share options to employees ⁽²⁾	-	-	-	-	-	46	-	46	-	46
Total transactions with owners of the Company	5,313	-	-	-	-	46	(2,662)	2,697	-	2,697
Transaction with non-controlling interests										
Subscription of shares in subsidiaries by non-controlling interests ^{(3) (4)}	-	-	-	-	-	-	-	-	341	341
Total transaction with non-controlling interests	-	-	-	-	-	-	-	-	341	341
At 30 September 2020	70,054	(105)	605	(3,572)	(4,463)	46	7,085	69,650	631	70,281

Statements of Changes in Equity

Group (Unaudited)	Attributable to owners of the company									Total equity S\$'000
	Share capital	Treasury share reserve	Foreign currency translation reserve	Merger reserve	Capital reserve	Share option reserve	Retained earnings	Equity attributable to owners of the company	Non-controlling interests	
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	
At 1 October 2020	70,054	(105)	605	(3,572)	(4,463)	46	7,085	69,650	631	70,281
Profit for the financial period	-	-	-	-	-	-	1,472	1,472	(51)	1,421
Other comprehensive income										
Foreign currency translation	-	-	(38)	-	-	-	-	(38)	-	(38)
Total comprehensive income for the financial period	-	-	(38)	-	-	-	1,472	1,434	(51)	1,383
Transaction with owners of the Company										
Grant of share options to employees ⁽²⁾	-	-	-	-	-	25	-	25	-	25
Dividends	-	-	-	-	-	-	-	-	-	-
Total transaction with owners of the Company	-	-	-	-	-	25	-	25	-	25
Transaction with non-controlling interests										
Subscription of shares in subsidiaries by non-controlling interests	-	-	-	-	-	-	-	-	-	-
Total transaction with non-controlling interests	-	-	-	-	-	-	-	-	-	-
At 31 December 2020	70,054	(105)	567	(3,572)	(4,463)	71	8,557	71,109	580	71,689

(1) On 27 February 2020, the Company, through its wholly-owned subsidiary, ISEC Sdn. Bhd. ("ISEC KL"), completed the acquisition of Indah Specialist Eye Centre Sdn. Bhd. ("Indah Specialist"), by way of the allotment and issuance of 17,950,913 consideration shares, equivalent to fair value consideration of S\$5,329,000 to the Vendors.

(2) The Company has granted 3,809,150 options under the ISEC Healthcare Share Option Scheme on 22 April 2020.

(3) As at 31 March 2020, ISEC Myanmar Company Limited ("ISEC Myanmar"), a 51% owned indirect subsidiary of the Company, has undertaken share capital injection, resulting in an increase from S\$1,365,000 (equivalent to US\$1,000,000) to S\$2,058,000 (equivalent to US\$1,500,000), through issuance of shares allotted to the existing shareholders of the subsidiary in equal proportion to their existing shareholdings.

(4) In July 2020, the Company, through its wholly-owned subsidiary, ISEC Sdn. Bhd. ("ISEC KL"), incorporated ISEC (Kuching) Sdn. Bhd. ("ISEC Kuching"), and 51% of the total shareholding is held by ISEC KL. The initial issued and paid-up share capital of ISEC Kuching was S\$3,000 (equivalent to RM10,000).

Statements of Changes in Equity

Group (Unaudited) (Restated)	Attributable to owners of the company							Non- controlling interests	Total equity
	Share capital	Treasury share reserve	Foreign currency translation reserve	Merger reserve	Capital reserve	Retained earnings	Equity attributable to owners of the company		
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000		
At 1 January 2019									
As previously reported	59,673	-	529	(3,572)	31	10,196	66,857	745	67,602
Effect of adoption of SFRS(I) 16	-	-	-	-	-	(166)	(166)	(29)	(195)
As restated	59,673	-	529	(3,572)	31	10,030	66,691	716	67,407
Profit for the financial period	-	-	-	-	-	5,121	5,121	(132)	4,989
Other comprehensive income									
Foreign currency translation	-	-	7	-	-	-	7	(3)	4
Total comprehensive income for the financial period	-	-	7	-	-	5,121	5,128	(135)	4,993
Transactions with owners of the Company									
Issuance of ordinary shares ⁽¹⁾	5,083	-	-	-	-	-	5,083	-	5,083
Shares issue expenses	(15)	-	-	-	-	-	(15)	-	(15)
Purchase of treasury shares	-	(105)	-	-	-	-	(105)	-	(105)
Dividends	-	-	-	-	-	(10,966)	(10,966)	-	(10,966)
Total transactions with owners of the Company	5,068	(105)	-	-	-	(10,966)	(6,003)	-	(6,003)
Transactions with non-controlling interests									
Subscription of shares in subsidiary by non-controlling interests ^{(2) (3)}	-	-	-	-	-	-	-	651	651
Acquisition of non-controlling interests' shares without a change in control ⁽¹⁾	-	-	-	-	(4,494)	-	(4,494)	(669)	(5,163)
Total transactions with non-controlling interests	-	-	-	-	(4,494)	-	(4,494)	(18)	(4,512)
At 30 September 2019	64,741	(105)	536	(3,572)	(4,463)	4,185	61,322	563	61,885

Statements of Changes in Equity

Group (Unaudited) (Restated)	Attributable to owners of the company							Non- controlling interests	Total equity
	Share capital	Treasury share reserve	Foreign currency translation reserve	Merger reserve	Capital reserve	Retained earnings	Equity attributable to owners of the company		
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000		
At 1 October 2019	64,741	(105)	536	(3,572)	(4,463)	4,185	61,322	563	61,885
Profit for the financial period	-	-	-	-	-	2,344	2,344	(84)	2,260
Other comprehensive income									
Foreign currency translation	-	-	(41)	-	-	-	(41)	(1)	(42)
Total comprehensive income for the financial period	-	-	(41)	-	-	2,344	2,303	(85)	2,218
At 31 December 2019	64,741	(105)	495	(3,572)	(4,463)	6,529	63,625	478	64,103

- (1) On 23 April 2019, the Company, through its wholly-owned subsidiary, ISEC Sdn. Bhd. ("ISEC KL"), completed the acquisition of the remaining 49% shareholding in ISEC (Penang) Sdn. Bhd. ("ISEC Penang"), by way of the allotment and issuance of 15,639,275 consideration shares, equivalent to fair value consideration of S\$5,083,000 to the non-controlling interests.
- (2) During the 9 months ended 30 September 2019, ISEC Myanmar Company Limited ("ISEC Myanmar"), a 51% owned indirect subsidiary of the Company, undertook four rounds of share capital injection, resulting in an increase from S\$39,000 (equivalent to US\$28,500) to S\$1,365,000 (equivalent to US\$1,000,000), through issuance of shares allotted to the existing shareholders of the subsidiary in equal proportion to their existing shareholdings.

Statements of Changes in Equity

	Share capital	Treasury share reserve	Share option reserve	Retained earnings	Total equity
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Company (Unaudited)					
At 1 January 2020	64,741	(105)	-	3,359	67,995
Profit for the financial period, representing total comprehensive income for the financial period	-	-	-	21	21
Transactions with owners of the Company					
Issuance of ordinary shares	5,329	-	-	-	5,329
Shares issue expenses	(16)	-	-	-	(16)
Grant of share options to employees ⁽¹⁾	-	-	46	-	46
Dividends	-	-	-	(2,662)	(2,662)
Total transactions with owners of the Company	5,313	-	46	(2,662)	2,697
At 30 September 2020	70,054	(105)	46	718	70,713
At 1 October 2020	70,054	(105)	46	718	70,713
Profit for the financial period, representing total comprehensive income for the financial period	-	-	-	4,315	4,315
Transaction with owners of the Company					
Grant of share options to employees ⁽¹⁾	-	-	25	-	25
Total transaction with owners of the Company	-	-	25	-	25
At 31 December 2020	70,054	(105)	71	5,033	75,053
Company (Unaudited)					
At 1 January 2019					
As previously reported	59,673	-	-	9,512	69,185
Effect of adoption of SFRS(I) 16	-	-	-	(3)	(3)
As restated	59,673	-	-	9,509	69,182
Profit for the financial period, representing total comprehensive income for the financial period	-	-	-	2,840	2,840
Transactions with owners of the Company					
Issuance of ordinary shares	5,083	-	-	-	5,083
Shares issue expenses	(15)	-	-	-	(15)
Purchase of treasury shares	-	(105)	-	-	(105)
Dividends	-	-	-	(10,966)	(10,966)
Total transactions with owners of the Company	5,068	(105)	-	(10,966)	(6,003)
At 30 September 2019	64,741	(105)	-	1,383	66,019
At 1 October 2019	64,741	(105)	-	1,383	66,019
Profit for the financial period, representing total comprehensive income for the financial period	-	-	-	1,976	1,976
At 31 December 2019	64,741	(105)	-	3,359	67,995

(1) The Company has granted 3,809,150 options under the ISEC Healthcare Share Option Scheme.

- 1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.**

Issued Share Capital

	Number of ordinary shares	Issued and paid- up share capital S\$'000
At 30 June 2020 and 31 December 2020	<u>550,685,857</u>	<u>70,054</u>

As at 31 December 2020, the number of ordinary shares in issue was 550,685,857 of which 386,400 were held by the Company as treasury shares. There were 386,400 treasury shares as at 31 December 2019.

Outstanding Convertibles

On 22 April 2020, the Company granted 3,809,150 options under the ISEC Healthcare Share Option Scheme, of which 427,590 options from the total 3,809,150 options were granted to 4 eligible Directors.

There were no share awards granted pursuant to the Company's performance share plan as at 31 December 2019 and 31 December 2020.

Save for the above, the Company did not have any outstanding options or convertibles, and there were no other options and share awards granted pursuant to the Company's employee share options scheme and performance share plan as at 31 December 2019 and 31 December 2020.

Treasury Shares

There were 386,400 treasury shares representing 0.07% of the Company's 550,299,457 ordinary shares (excluding treasury shares) as at 31 December 2020. There were 386,400 treasury shares representing 0.07% as at 31 December 2019.

Subsidiary Holdings

There were no subsidiary holdings as at 31 December 2019 and 31 December 2020.

1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year

	<u>As at 31 December 2020</u>	<u>As at 31 December 2019</u>
Total number of issued shares (excluding treasury shares)	550,299,457	532,348,544

1(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

Not applicable. There were no sales, transfers, cancellation and/or use of treasury shares during and as at the end of the current financial period reported on.

1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.

Not applicable. There were no subsidiary holdings during and as at the end of the current financial period reported on.

2. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice

The figures have not been audited or reviewed by the Company's auditors.

3. Where the figures have been audited or reviewed, the auditors' report (including any modifications or emphasis of a matter)

Not applicable.

3A. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:-

(a) Updates on the efforts taken to resolve each outstanding audit issue.

(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

Not applicable as the Group's financials are not subject to an adverse opinion, qualified opinion or disclaimer of opinion.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied

Except as disclosed in paragraph 5 below, the accounting policies and methods of computation adopted in the financial statements for the current financial reporting period are consistent with those disclosed in the audited financial statements for the financial year ended 31 December 2019.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change

The accounting policies adopted are consistent with those of the previous financial year except in the current financial year, the Group has adopted all the new and revised standards which are effective for the financial period beginning on or after 1 January 2020. The adoption of these new standards, amendments to standards and interpretations did not result in any significant impact on the financial statements of the Group.

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends

	Group		Group	
	3 months ended		12 months ended	
	31 December 2020 (Unaudited)	31 December 2019 (Unaudited)	31 December 2020 (Unaudited)	31 December 2019 (Audited)
Earnings per share ("EPS")				
Profit attributable to owners of the parent (S\$'000)	1,472	2,344	4,690	7,465
Weighted average number of ordinary shares in issue (excluding treasury shares)	550,299,457	532,348,544	547,503,823	527,569,833
Basic (Singapore cents)	0.27	0.44	0.86	1.41
Weighted average number of ordinary shares in issue (excluding treasury shares)	550,351,098	532,348,544	547,539,661	527,569,833
Fully diluted basis (Singapore cents) ⁽¹⁾	0.27	0.44	0.86	1.41

7. **Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the**
- (a) **Current financial period reported on; and**
- (b) **Immediately preceding financial year**

	Group		Company	
	31 December 2020	31 December 2019	31 December 2020	31 December 2019
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Net asset value attributable to owners of the parent (S\$'000)	71,109	63,625	75,053	67,995
Number of ordinary shares in issue (excluding treasury shares)	550,299,457	532,348,544	550,299,457	532,348,544
Net asset value per ordinary share (S\$)	0.13	0.12	0.14	0.13

8. **A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss:-**
- (a) **any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**
- (b) **any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.**

Review of comparative performance of the Group for the financial year ended 31 December 2020 ("FY2020") and 31 December 2019 ("FY2019").

Consolidated Statement of Comprehensive Income

Revenue

The Group recorded revenue of S\$36.33 million in FY2020, a decrease of 15% from S\$42.87 million in FY2019. Excluding contribution from Indah Specialist of S\$3.15 million, which acquisition was completed in February 2020, the Group's revenue for FY2020 showed a decrease of S\$9.70 million, or 23%, compared to that for FY2019. The Group's business activities in both Malaysia and Singapore were generally adversely affected due to the outbreak of COVID-19 in FY2020.

Revenue from Singapore operations reduced by 24%, from S\$9.50 million in FY2019 to S\$7.26 million in FY2020. Patient visits decreased significantly in April and May 2020 due to the implementation of Circuit Breaker ("CB"). Additionally, the reduction in business was also contributed by the entry restrictions imposed on foreign patients seeking healthcare treatment in Singapore.

As the country entered into Phase 2 on 19 June 2020, all eye consultations and procedures were allowed to be performed and the revenue gradually increased. Despite the restrictions of foreign patient visits and the requirements of safe distancing measures, patient visits were improving gradually. Singapore entered Phase 3 of the country's reopening on 28 December 2020, during which foreign patients are still prohibited from entering Singapore to seek healthcare treatment.

In Malaysia, revenue decreased by S\$4.56 million, or 14%, from S\$33.22 million in FY2019 to S\$28.66 million in FY2020. The enforcement of the Movement Control Order ("MCO") led to the slowing down of economic activity. The country entered the "Recovery Movement Control Order" ("RMCO") on 10 June 2020, with further restrictions eased and interstate travels allowed. The MCO and RMCO led to a decrease in business activities with the various travel restrictions and safe distancing measures imposed, as well as the entry restrictions imposed on foreign patients seeking healthcare treatment in Malaysia.

Malaysia had seen COVID-19 cases significantly increased since December 2020, and the country had entered into MCO again since 13 January 2021.

Cost of sales

Cost of sales decreased by 11%, or S\$2.55 million, from S\$22.82 million in FY2019 to S\$20.27 million in FY2020. Excluding contribution from Indah Specialist, the Group's cost of sales for FY2020 showed a decrease of S\$4.24 million, or 19%, compared to that for FY2019. This was attributable to decreased business activities as described above. The extent of decrease in cost of sales was lower as compared to the drop in revenue mainly due to an increase in headcount of specialised doctors, from 30 in FY2019 to 34 in FY2020.

Gross profit and gross profit margin

Gross profit decreased by 20% to S\$16.06 million in FY2020 with a decrease in gross profit margin of 2.6 percentage points, from 46.8% in FY2019 to 44.2% in FY2020. Excluding contribution by Indah Specialist, gross profit decreased by 27%, or S\$5.45 million to S\$14.60 million in FY2020, with a decrease in gross profit margin of 2.8 percentage points, to 44.0% in FY2020. This was mainly due to the decreased business activities in both Singapore and Malaysia due to the outbreak of the COVID-19.

Other income

Other income increased by 89%, from S\$0.70 million in FY2019 to S\$1.33 million in FY2020, mainly due to increased government grants by Singapore and Malaysia by S\$0.55 million, rental rebates of S\$0.13 million and increase in profit guarantee from vendors of subsidiaries acquired, by S\$0.07 million. The government grants and rental rebates were part of the respective governments' support measures to relief operations affected by COVID-19.

The increase in other income was partially offset by decreased interest income by S\$0.19 million, mainly attributable to reduced interest rates from the financial institutions.

Other expenses

The Group has recognised other expenses of S\$2.05 million in FY2020, compared to S\$1.82 million in FY2019. An impairment loss for goodwill, totaling S\$1.48 million, in the general health services segment, arising from S\$0.38 million relating to JL Medical (Bukit Batok) Pte. Ltd. ("JLMBB"), S\$0.30

million relating to JL Medical (Woodlands) Pte. Ltd. ("JLMWL"), and S\$0.80 million relating to JL Medical (Yew Tee) Pte. Ltd. ("JLMYT") respectively, was recognised in FY2020.

An impairment loss for goodwill amounting to S\$1.18 million, S\$0.80 million relating to JL Medical (Sembawang) Pte. Ltd. ("JLMSB") and S\$0.38 million relating to JLMWL, was recognised in FY2019.

The recoverable amounts of the cash-generating units ("CGUs") have been determined based on the cash flow forecasts of the respective CGU from the updated financial budgets, taking into consideration the impact of COVID-19 on the respective CGUs' forecasted growth rates, with a five-year period and projection to terminal year.

The forecasted growth rates are based on expectations for each CGU from historical trends, its current impact from COVID-19 and expected growth rates as a result, and planned business strategies, as well as long-term average growth rates of the healthcare industry in the respective countries.

In view of the expected decline in earnings in the general health services segment due to COVID-19, additional impairment loss for goodwill of S\$1.48 million was recorded in FY2020 (FY2019: S\$1.18 million).

Finance costs

Finance costs increased from S\$0.26 million in FY2019 to S\$0.42 million in FY2020, mainly relating to the purchase consideration for the acquisition of Indah Specialist payable to the vendors, hence the unwinding of discount of S\$0.09 million, and S\$0.04 million of interest expense arising from bank loan undertaken to partially finance the acquisition of land and building in Penang.

Income tax expense

The effective tax rates of the Group in FY2019 and FY2020 were 27% and 32% respectively. Had the impairment loss for goodwill been excluded, effective tax rate of the Group in FY2019 and FY2020 would have been 24% and 26% respectively. For FY2020, the statutory corporate tax rates are 17% in Singapore, 24% in Malaysia and 25% in Myanmar. The taxable profits had decreased in FY2020 compared to that in FY2019, however the presence of non-deductible expenses of approximately S\$0.08 million recognised in relation to fees incurred for the purchase of land and building in Penang, resulted in higher effective tax rates in FY2020 compared to that in FY2019.

Profit after tax

Net profit of the Group in FY2020 was S\$4.45 million, a decrease of S\$2.80 million compared to S\$7.25 million in FY2019, mainly due to the above-mentioned factors.

Review of comparative financial position of the Group for the financial year ended 31 December 2020 and 31 December 2019.

Consolidated Statement of Financial Position

Non-current assets

Non-current assets increased by S\$14.72 million to S\$59.65 million as at 31 December 2020 mainly due to the following:

- 1) Recognition of goodwill of S\$10.02 million, arising from the acquisition of Indah Specialist which was completed on 27 February 2020. The goodwill of S\$10.02 million was arrived at based on the excess of the fair value purchase consideration of S\$11.21 million over the fair value of net assets acquired at completion date of S\$1.06 million, less S\$0.13 million from the Singapore Dollar translated carrying value of the goodwill as at 31 December 2020;
- 2) Purchase of property by the Group's indirect subsidiary, ISEC (Penang) Sdn. Bhd. ("ISEC Penang"), of S\$6.19 million (equivalent to RM18.92 million) in August 2020, for expansion purpose;
- 3) Renewal of clinic premise and office lease agreement of approximately S\$2.13 million, classified as right-of-use assets;
- 4) Plant and equipment additions arising from the acquisition of Indah Specialist of S\$0.52 million;
- 5) Plant and equipment additions of S\$0.44 million relating mainly to medical equipment, computer hardware, etc. to replace existing assets; and
- 6) Clinic system software purchase of S\$0.11 million in Malaysia.

The increase in non-current assets was partially offset by the following:

- 1) Depreciation expenses of right-of-use assets of S\$1.54 million;
- 2) Depreciation expenses of plant and equipment of S\$1.11 million;
- 3) Impairment loss for goodwill of S\$1.48 million; and
- 4) Amortisation expenses of intangible assets of S\$0.60 million.

Current assets

Current assets decreased by S\$1.41 million to S\$28.83 million mainly due to the following:

- 1) Decrease in cash and cash equivalents of S\$1.53 million due to reasons mentioned in review of cash flows of the group; and
- 2) Decrease in trade receivables by S\$0.23 million which is in line with the reduction of business activities during the year.

The decrease in current assets was partially offset by the following:

- 1) Increase in other receivables and deposits by S\$0.22 million, mainly due to accrual for profit guarantee from vendors of subsidiaries acquired of S\$0.14 million and recognition of S\$0.03 million of accrued government grant income.

Non-current liabilities

Non-current liabilities increased by S\$4.07 million to S\$7.85 million as at 31 December 2020 mainly

due to the following:

- 1) Bank loan of S\$3.14 million arising from the purchase of property by the Group's indirect subsidiary, ISEC Penang;
- 2) Net increase of lease liabilities of S\$0.44 million, arising mainly from the renewal of office and clinic premise lease agreement of S\$2.13 million, less lease payments made during the year; and
- 3) Portion of balance purchase consideration for the acquisition of Indah Specialist of S\$0.56 million payable within 24 months from the acquisition date.

Current liabilities

Current liabilities increased by S\$1.65 million to S\$8.94 million as at 31 December 2020 mainly from the portion of balance purchase consideration for the acquisition of Indah Specialist of S\$1.70 million payable within the next 12 months, and the bank loan of S\$0.87 million arising from the purchase of property by the Group's indirect subsidiary, ISEC Penang.

The increase was offset by decreased payroll payable by S\$0.64 million with decreased provision for bonuses resulting from decreased business activities. Likewise, trade payables and current income tax payable decreased by S\$0.29 million and S\$0.15 million respectively with decreased business activities.

Review of cash flows of the Group for FY2020.

Consolidated Statement of Cash Flows

As at 31 December 2020, the Group had cash and cash equivalents of S\$24.12 million, as compared to S\$25.66 million of cash and cash equivalents as at 31 December 2019.

Cash flows from operating activities

In FY2020, net cash flows from operating activities was S\$7.87 million. This comprised operating cash flows before working capital changes of S\$11.29 million, and changes in working capital outflow of S\$1.14 million, largely from trade and other payables mainly due to payout of remuneration and bonus to doctors and staff, less income tax paid of S\$2.28 million.

Cash flows used in investing activities

Net cash used in investing activities in FY2020 amounted to S\$5.07 million mainly due to the cash consideration of acquisition of Indah Specialist of S\$2.95 million and purchases of property, plant and equipment of S\$2.31 million of which S\$1.94 million related to the land and building purchase in Penang. In FY2020, a new clinic system software was also procured by our Malaysia operations, amounting to S\$0.11 million. The cash outflow was offset by interest income received of S\$0.30 million.

Cash flows used in financing activities

Net cash used in financing activities was S\$4.35 million in FY2020, mainly due to dividend of S\$2.66 million paid to shareholders of the Company, repayment of lease liabilities and its corresponding finance costs which aggregated to S\$1.70 million, and repayment of bank loan and its corresponding

finance costs which aggregated to S\$0.32 million. The cash outflow was offset by cash inflow of S\$0.34 million, arising from additional capital injection by the non-controlling interests in ISEC Myanmar and ISEC Kuching.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

The current financial period's results are in line with the Group's expectations as disclosed in the Group's HY2020 results announcement (Section 10) released on 12 August 2020 and the unaudited financial statement voluntary announcement for the third quarter ended 30 September 2020 (Section 3) released on 21 October 2020.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

In Malaysia, Movement Control Order ("MCO") was initially re-imposed in six states and territories on 13 January 2021 due to the spike in reported COVID-19 cases. The affected areas include Selangor, Melaka, Penang, Johor, Sabah and Kuala Lumpur, of which all our eye clinic operations are located. In the same month, MCO was extended to all states and federal territories, except Sarawak, to curb the spread of COVID-19. On 2 February 2021, the MCO would be extended till 4 March 2021. Similar to the previous MCO and CMCO, this consists of a ban on travelling between states and strict restrictions on household movement. Additionally, the King declared Malaysia's state of emergency on the 12 January 2021, which will last until 1 August 2021 or earlier, depending on the COVID-19 situation in the country. Though our clinics remain open for operations, the management does not expect all the specialised eye centres in Malaysia to be recovering soon to pre-COVID-19 state as the country's economic recovery is expected to be affected. The Group will closely monitor the impact of the situation and make the necessary operational adjustments accordingly as the situation deems fit throughout the year and beyond.

With the COVID-19 outbreak under control, Singapore entered into Phase 3 of Circuit Breaker ("CB") since 28 December 2020, whereby safety control measures and global travel restrictions are progressively relaxed and economic activities slowly recover. Vaccination has also been rolled out sometime end of January 2020. Nonetheless, some clusters of community spreads are still prevalent. The Group will continue to monitor the progress in the country closely and assess its impact to the Group's operations accordingly.

In Myanmar, the country had on 1 February 2021 declared a state of emergency for a year for political reasons. The clinic is currently still operational with lower patient load. The management does not expect the situation to materially affect the Group's revenue as a whole. However, the on-going protest may adversely affect the operations of the clinic. We will monitor the situation there.

11. Dividend

- (a) Whether an interim (final) ordinary dividend has been declared (recommended); and**

Yes.

- (b) (i) Amount per share (cents)**

Name of dividend	Final Dividend
Dividend type	Cash
Dividend rate	0.80 Singapore cents (S\$0.0080) per ordinary share
Tax rate	Tax exempt (one-tier)

- (ii) Previous corresponding period (cents)**

Name of dividend	Final Dividend
Dividend type	Cash
Dividend rate	0.50 Singapore cents (S\$0.0050) per ordinary share
Tax rate	Tax exempt (one-tier)

In addition, a first interim cash dividend (tax exempt one-tier) of 0.30 Singapore cents (S\$0.0030) per ordinary share was declared for the 6 months ended 30 June 2019 and paid on 28 August 2019.

- (c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).**

The proposed final dividend is tax exempt (one-tier) dividend.

- (d) The date the dividend is payable.**

The proposed final dividend is subject to the approval of shareholders at the forthcoming annual general meeting of the Company ("AGM"). The dividends will be paid on 6 May 2021 if approved by shareholders.

- (e) The date on which Registrable Transfers received by the Company (up to 5.00pm) will be registered before entitlements to the dividend are determined.**

Subject to the approval of shareholders at the forthcoming AGM, the Share Transfer Books and Register of Members of the Company will be closed at 5:00 p.m. on 29 April 2021 for the purpose of determining shareholders' entitlements to the proposed final tax exempt (one-

tier) dividend in respect of the financial year ended 31 December 2020 (“**Proposed Dividend**”).

Duly completed registrable transfers received by the Company’s Share Registrar, Boardroom Corporate & Advisory Services Pte. Ltd., at 50 Raffles Place #32-01 Singapore Land Tower, Singapore 048623 up to 5.00 p.m. on 29 April 2021 will be registered to determine shareholders’ entitlements to the Proposed Dividend. Shareholders whose securities accounts with The Central Depository (Pte) Limited are credited with the Company’s shares at 5.00 p.m. on 29 April 2021 will be entitled to the Proposed Dividend.

12. If no dividend has been declared/recommended, a statement to that effect and the reason(s) for the decision.

Not applicable.

13. If the group has obtained a general mandate from shareholders for interested person transactions (“IPT”), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Company did not obtain a general mandate from shareholders for IPTs.

There was no IPT amounting to S\$100,000 and above for the fourth quarter ended 31 December 2020 and FY2020.

14. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1)

The Company confirms that undertakings have been procured from the Board of Directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1).

PART II – ADDITIONAL INFORMATION REQUIRED FOR FULL YEAR ANNOUNCEMENT (This part is not applicable to Q1, Q2, Q3 or Half Year Results)

- 15. Segmented revenue and results for operating segments (of the group) in the form presented in the issuer’s most recently audited annual financial statements, with comparative information for the immediately preceding year.**

Business segments

The Group has two reportable segments as described below.

- Specialised health services: provision of medical care, consultancy, treatment and surgery in the field of ophthalmology; and
- General health services: provision of general medical services.

	12 Months Ended	
	31 December 2020 S\$'000	31 December 2019 S\$'000
Segment revenue		
Specialised health services	32,818	38,821
General health services	3,509	4,051
Total	<u>36,327</u>	<u>42,872</u>
Segment profit after tax		
Specialised health services	4,996	7,377
General health services	(545)	(128)
Total	<u>4,451</u>	<u>7,249</u>

Geographical segments

The Group operates in Singapore, Malaysia and Myanmar.

	12 Months Ended	
	31 December 2020 S\$'000	31 December 2019 S\$'000
Segment revenue		
Singapore	7,263	9,497
Malaysia	28,662	33,221
Myanmar	402	154
Total	<u>36,327</u>	<u>42,872</u>
Segment profit/(loss) after tax		
Singapore	(297)	1,009
Malaysia	5,163	6,781
Myanmar	(415)	(541)
Total	<u>4,451</u>	<u>7,249</u>

16. In the review of performance, the factors leading to any material changes in distribution to turnover and earnings by operating segments.

Performance by business segments

Specialised health services:

Revenue decreased by S\$6.00 million, or 15%, from S\$38.82 million in FY2019 to S\$32.82 million in FY2020. Revenue from specialised health services were adversely affected due to the outbreak of COVID-19. In Singapore, non-essential eye consultations and procedures were not allowed to be performed during 7 April 2020 to 1 June 2020, when “circuit breaker” measures were introduced to reduce movements and interactions locally and internationally. Post circuit breaker such limited movements and interactions have continued to be observed when Singapore progressively relaxed certain controls. Similarly, national movement control order measures were introduced since 18 March 2020 in Malaysia which significantly reduced the number of foreign patient visits.

Profit after tax decreased by S\$2.38 million, or 32% between both years mainly as a result from impact due to COVID-19.

General health services:

General health services were also adversely affected from the outbreak of COVID-19, with revenue reduced by 13%, from S\$4.05 million in FY2019 to S\$3.51 million in FY2020.

Profit after tax decreased by S\$0.42 million in FY2020 compared to a S\$0.13 million in FY2019, mainly as a result from impact due to COVID-19.

Performance by geographical segments

Singapore operations:

Please refer to Paragraph 8.

Malaysia operations:

Please refer to Paragraph 8.

Myanmar operations:

Revenue from Myanmar operations has increased from S\$0.15 million in FY2019 to S\$0.40 million. Our business operations in Myanmar commenced in second quarter ended 30 June 2019, and certain treatments and procedures were only allowed to be carried out after ISEC Myanmar officially attained the business license from the Ministry of Health and Sports in Myanmar near end 2019.

The loss after tax in FY2020 was mainly due to the recurring fixed costs, mainly comprising depreciation expenses and staff costs.

17. Breakdown of sales in the first half and second half of the financial year

	Group		
	12 Months Ended		Increase
	31 December 2020	31 December 2019	
	(Unaudited) S\$'000	(Unaudited) S\$'000	%
Sales reported for first half year	15,038	20,429	-26%
Operating profit after tax before deducting non-controlling interests reported for first half year	500	3,315	-85%
Sales reported for second half year	21,289	22,443	-5%
Operating profit after tax before deducting non-controlling interests reported for second half year	3,951	3,934	0.4%

18. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year

	FY2020 (Unaudited) S\$'000	FY2019 (Audited) S\$'000
Ordinary-Interim	-	1,598
Ordinary-Final	4,402 ⁽¹⁾	2,663
Special	-	-
Preference	-	-
Total	4,402	4,261

⁽¹⁾ The proposed final cash dividend (tax exempt one-tier) of 0.80 Singapore cents (S\$0.0080) per ordinary share of the Company will be subject to approval by shareholders at the forthcoming AGM to be convened.

19. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(10) in the format below. If there are no such persons, the issuer must take an appropriate negative statement.

Save as disclosed below, the Company confirms that there is no person occupying a managerial position in the Company or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the Company as at the date of this announcement.

Name	Age	Family relationship with any director, chief executive officer and/or substantial shareholder	Current position and duties, and the year the position was held	Details of changes in duties and position held, if any, during the year
Dr Lee Yeng Fen	55	Spouse of Dr Lee Hung Ming, Executive Vice Chairman	Group Medical Director, JLM Companies (2016)	None

20. Disclosures on Acquisition and Realisation of Shares pursuant to Catalist Rule 706A

On 27 February 2020, the Company completed the acquisition of Indah Specialist through its wholly-owned subsidiary, ISEC Sdn. Bhd. from external parties (Lee Peng Hwa, Woi You Wan, Lim Siew Geok, Loh Swee Seng, Siow Yun Ching and Tan Siow Wei. Collectively, the “Vendors”). The entire issued and paid up share capital of Indah Specialist was acquired by way of allotment of 17,950,913 new ordinary shares to the Vendors at the price of S\$0.356 per share on issue date and cash consideration of RM17,932,800.

Following the allotment and issuance of the new ordinary shares, the total number of issued and fully paid-up shares (excluding treasury shares) has increased from 532,348,544 to 550,299,457.

The Company’s 25%-owned associate, I Medical & Aesthetics Pte. Ltd., had on 12 January 2021 disposed of 36,780 of its 100,000 ordinary shares (100,000 ordinary shares represented 50% ownership) held in an entity, i.Dental & i.Medical Pte. Ltd. (“IDIM”), to the other shareholder in which it co-owned, for a consideration of S\$36,780, being the original cost consideration for the 36,780 ordinary shares. The consideration will be satisfied via cheque payment by the other shareholder. The net asset value (unaudited) of IDIM was S\$35.00 as at 31 December 2020.

BY ORDER OF THE BOARD

Dr Lee Hung Ming
Executive Vice Chairman
25 February 2021

This announcement has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”) and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms Gillian Goh, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.